Answers are grounded in this paper and cite their sources.
In 4 studies on 3 acromegalic patients, who had normal iv glucose tolerance and high insulin response to infused glucose (Al), the oxidation to 14 CO 2 of [2- 14 C] pyruvate (injected intravenously in trace amount after overnight fast) was not different from that in 9 studies of 9 nonacromegalic »high insulin responders« (Ni). In 4 studies on 3 other acromegalic patients, who had low glucose tolerance and less insulin response to glucose (A2), the formation of 14 CO 2 was reduced to ½–⅔ that of Al or N1 and was about proportionate to the reduction in glucose tolerance. In A2 the 14 CO 2 formation was slightly lower than the mean for 10 studies with 7 non-acromegalic subjects, who were »low insulin responders« with normal or low glucose tolerance (N2). Among non-acromegalics expiration of 14 CO 2 was significantly lower in N2 than in N1. Among 4 non-acromegalic subjects treated with human growth hormone for 3–4 days one had a marked reduction in pyruvate oxidation, while all had a decrease in glucose tolerance. Analysis of 14 C in blood glucose at 60 minutes after injection of [2- 14 C]pyruvate suggested that slightly more total 14 C-glucose was present in A2 than N1 without any differences between A2 and N2 or N1 and N2. Two out of 4 studies in A1 showed lower than normal amounts of 14 Cglucose. No change in 14 C-glucose occurred after administration of HGH. The findings suggest that impairment of pyruvate oxidation accompanies a lowered glucose tolerance in acromegalics with a diabetic tendency. Changes in gluconeogenesis from pyruvate appear to be minimal.
No takes yet. Share an insight, caveat, or question.
Shreeve et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: